CO5261626A1 - Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialemente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologica - Google Patents
Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialemente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicaInfo
- Publication number
- CO5261626A1 CO5261626A1 CO01003816A CO01003816A CO5261626A1 CO 5261626 A1 CO5261626 A1 CO 5261626A1 CO 01003816 A CO01003816 A CO 01003816A CO 01003816 A CO01003816 A CO 01003816A CO 5261626 A1 CO5261626 A1 CO 5261626A1
- Authority
- CO
- Colombia
- Prior art keywords
- group
- radical
- formula
- atoms
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
Abstract
Glutarimidas sustituidas, caracterizadas por la fórmula general I <EMI FILE="01003816_1" ID="1" IMF=JPEG >en la cual X significa un grupo de fórmula (CH2)n-(CR8R9)p-Z-(CR8R9)m; Z representa un átomo de azufre o de oxígeno, el grupo SO o SO2, el radical NR8 (en caso dado en la forma del óxido de N) o un grupo CR8R9; m y p representan 0 ó 1; n representa 0, 1, 2 ó 3; en donde m, n y p no pueden ser simultáneamente 0; R1 y R2 son iguales o diferentes y representan un grupo carboxilo, un grupo éster de fórmula COOR5 o un grupo acilo de fórmula COR5, grupos en los cuales R5 significa en cada caso un grupo alquilo (de cadena recta o ramificada) con 1 a 6 átomos de C (en caso dado sustituido con el radical COOR5 y/o un grupo fenilo), un grupo cicloalquilo C3 a C7 o un radical fenilo o bencilo; o un grupo amida de fórmula CONR6R7, en el cual R6 y R7 son iguales o diferentes y representan hidrógeno, un grupo alquilo (de cadena recta o ramificada) con 1 a 6 átomos de C (en caso dado sustituido con el radical COOR5 y/o un grupo fenilo), el radical alquilo, el radical fenilo o, conjuntamente con el átomo de N, el grupo hidrazida, el anillo pirrolidina, piperidina, hexametilenimina, morfolina, tiomorfolina, piperazina o N-metilpiperazina; o - 2 - hidrógeno, bromo, cloro, flúor, un grupo mono-, di- o trifluorometilo, tritilo, hidroxi, hidroximetilo, trifluorometoxi, nitro, amino (en caso dado sustituido con el radical CH(=O) o COR5 o un grupo alquilsulfonilo) o dimetilamino, un radical alquilo o alcoxi (de cadena recta o ramificada) con 1 a 6 átomos de C, un radical amidina de fórmula NH-CH(=NH) o NH-C(=NH)R5, un radical fenilo o un anillo de benceno unido por condensación (sustituido en caso dado con los átomos o grupos arriba mencionados); con la condición de que cuando Z = CR8R9, entonces R1 y R2 no pueden representar simultáneamente hidrógeno, y cuando Z = S y m = 0, entonces R1 y R2 no pueden representar el grupo metoxi; R3 representa hidrógeno, el radical hidroxi o un grupo de fórmula CH2-NR6R7, en la cual R6 y R7 son los arriba definidos; R4 representa hidrógeno, un grupo alquilo C1 a C3, un átomo de flúor, el grupo difluoro- o trifluorometilo; R8 representa hidrógeno, un grupo alquilo con 1 a 4 átomos de C (de cadena recta o ramificada), el radical bencilo o fenetilo (en caso dado sustituido con los átomos o grupos previamente mencionados); y R9 tiene el mismo significado de R8 y representa el grupo éster de fórmula COOR5, el radical fenilo, el grupo hidroxi o un radical alcoxi (de cadena recta o ramificada) con 1 a 4 átomos de C, un átomo de flúor o cloro, o el grupo trifluorometilo; y sus enantiómeros, mezclas de enantiómeros, racematos, diastereómeros o mezclas de diastereómeros en la forma de sus bases o sales de ácidos fisiológicamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10002509A DE10002509A1 (de) | 2000-01-21 | 2000-01-21 | Substituierte Glutarimide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5261626A1 true CO5261626A1 (es) | 2003-03-31 |
Family
ID=7628270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO01003816A CO5261626A1 (es) | 2000-01-21 | 2001-01-19 | Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialemente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologica |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6656937B2 (es) |
| EP (1) | EP1252144B1 (es) |
| JP (1) | JP2003524641A (es) |
| KR (1) | KR20020067614A (es) |
| CN (1) | CN1185215C (es) |
| AR (1) | AR030185A1 (es) |
| AT (1) | ATE451355T1 (es) |
| AU (1) | AU780636B2 (es) |
| BR (1) | BR0108030A (es) |
| CA (1) | CA2398061A1 (es) |
| CO (1) | CO5261626A1 (es) |
| CY (1) | CY1109784T1 (es) |
| DE (2) | DE10002509A1 (es) |
| DK (1) | DK1252144T3 (es) |
| ES (1) | ES2337875T3 (es) |
| HU (1) | HUP0204235A3 (es) |
| IL (1) | IL150813A0 (es) |
| MX (1) | MXPA02007089A (es) |
| NO (1) | NO323395B1 (es) |
| NZ (1) | NZ520759A (es) |
| PE (1) | PE20011067A1 (es) |
| PL (1) | PL356986A1 (es) |
| PT (1) | PT1252144E (es) |
| RU (1) | RU2278857C2 (es) |
| SI (1) | SI1252144T1 (es) |
| SK (1) | SK287173B6 (es) |
| WO (1) | WO2001053261A1 (es) |
| ZA (1) | ZA200206664B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
| US7842727B2 (en) | 2001-03-27 | 2010-11-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| DE10163595A1 (de) * | 2001-12-21 | 2003-08-07 | Gruenenthal Gmbh | In 3-Position heterocyclisch substituierte Piperidin-2,6-dione |
| EP1511477A4 (en) | 2002-05-22 | 2008-04-09 | Errant Gene Therapeutics Llc | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS |
| CA2486385C (en) * | 2002-05-22 | 2013-12-10 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds |
| US20040192738A1 (en) * | 2003-03-18 | 2004-09-30 | Aventis Pharma Deutschland Gmbh | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it |
| KR20060124770A (ko) | 2004-03-17 | 2006-12-05 | 화이자 프로덕츠 인코포레이티드 | 벤질(이덴)-락탐 유도체 |
| DE102004026703A1 (de) * | 2004-05-28 | 2005-12-29 | Grünenthal GmbH | Verfahren zur Herstellung von in 3-Position heterocyclisch substituierten Piperidin-2,6-dionen |
| CN105189478B (zh) | 2013-01-07 | 2019-10-22 | 南加州大学 | 脱氧尿苷三磷酸酶抑制剂 |
| BR122020010204B1 (pt) * | 2013-04-12 | 2022-03-03 | Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" | Composto derivado de glutarimida, seu uso, composiçâo farmacêutica e método de de preparação |
| CA2935717C (en) | 2014-01-03 | 2022-06-21 | University Of Southern California | Uracil isostere and pharmaceutical compositions thereof useful as deoxyuridine triphosphatase inhibitors |
| US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| EA037990B1 (ru) | 2015-07-08 | 2021-06-21 | Св6 Терапьютикс (Най) Лимитед | Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин |
| US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| US10570100B2 (en) | 2015-07-08 | 2020-02-25 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| RU2610275C2 (ru) * | 2015-07-30 | 2017-02-08 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения |
| KR102520814B1 (ko) * | 2016-03-16 | 2023-04-11 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | 작동자 t 세포 기능 개선을 위한 세레브론에 대한 소분자 |
| US11168059B2 (en) | 2016-11-23 | 2021-11-09 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
| EA201992341A8 (ru) * | 2017-09-07 | 2020-08-11 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3684365A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND USES OF SUCH |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) * | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CN107857754B (zh) * | 2018-01-15 | 2018-11-09 | 泰山医学院 | 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用 |
| CN107903245B (zh) * | 2018-01-15 | 2018-11-13 | 青岛大学附属医院 | 一种化合物及其在制备治疗类风湿性关节炎药物中的应用 |
| EP3817748A4 (en) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | TRICYCLIC CRBN LIGANDS AND USES THEREOF |
| CA3105506A1 (en) | 2018-07-11 | 2020-01-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
| JP2022516401A (ja) | 2018-11-30 | 2022-02-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| SG11202110829YA (en) | 2019-04-05 | 2021-10-28 | Kymera Therapeutics Inc | Stat degraders and uses thereof |
| MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| AU2020412780A1 (en) | 2019-12-23 | 2022-07-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| BR112022018678A2 (pt) | 2020-03-19 | 2022-11-01 | Kymera Therapeutics Inc | Degradadores de mdm2 e usos dos mesmos |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| BR112022026356A2 (pt) * | 2020-06-26 | 2023-01-17 | Valenta Intellekt Ltd | Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6 |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2673205A (en) * | 1951-02-13 | 1954-03-23 | Ciba Pharm Prod Inc | 3-disubstituted dioxopiperidines and the manufacture thereof |
| US3214431A (en) * | 1958-08-04 | 1965-10-26 | Pfizer & Co C | Novel glutarimides |
| US5114937A (en) * | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| GB8928043D0 (en) * | 1989-12-12 | 1990-02-14 | Pfizer Ltd | Muscarinic receptor antagonists |
| FR2745811B1 (fr) * | 1996-03-07 | 1998-05-22 | Sanofi Sa | Glutarimide disubstitue procede pour sa preparation, et son utilisation |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| DE19703763C1 (de) * | 1997-02-01 | 1998-10-01 | Gruenenthal Gmbh | Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione |
| DE19843793C2 (de) * | 1998-09-24 | 2000-08-03 | Gruenenthal Gmbh | Substituierte Benzamide |
| DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
-
2000
- 2000-01-21 DE DE10002509A patent/DE10002509A1/de not_active Ceased
-
2001
- 2001-01-09 WO PCT/EP2001/000155 patent/WO2001053261A1/de active IP Right Grant
- 2001-01-09 PL PL01356986A patent/PL356986A1/xx not_active Application Discontinuation
- 2001-01-09 AU AU25140/01A patent/AU780636B2/en not_active Ceased
- 2001-01-09 DK DK01900400.1T patent/DK1252144T3/da active
- 2001-01-09 BR BR0108030-0A patent/BR0108030A/pt not_active IP Right Cessation
- 2001-01-09 RU RU2002121641/04A patent/RU2278857C2/ru not_active IP Right Cessation
- 2001-01-09 JP JP2001553265A patent/JP2003524641A/ja not_active Withdrawn
- 2001-01-09 CA CA002398061A patent/CA2398061A1/en not_active Abandoned
- 2001-01-09 DE DE50115252T patent/DE50115252D1/de not_active Expired - Lifetime
- 2001-01-09 IL IL15081301A patent/IL150813A0/xx unknown
- 2001-01-09 ES ES01900400T patent/ES2337875T3/es not_active Expired - Lifetime
- 2001-01-09 SI SI200130961T patent/SI1252144T1/sl unknown
- 2001-01-09 AT AT01900400T patent/ATE451355T1/de not_active IP Right Cessation
- 2001-01-09 SK SK1017-2002A patent/SK287173B6/sk not_active IP Right Cessation
- 2001-01-09 MX MXPA02007089A patent/MXPA02007089A/es active IP Right Grant
- 2001-01-09 CN CNB018038883A patent/CN1185215C/zh not_active Expired - Fee Related
- 2001-01-09 PT PT01900400T patent/PT1252144E/pt unknown
- 2001-01-09 EP EP01900400A patent/EP1252144B1/de not_active Expired - Lifetime
- 2001-01-09 HU HU0204235A patent/HUP0204235A3/hu unknown
- 2001-01-09 NZ NZ520759A patent/NZ520759A/en unknown
- 2001-01-09 KR KR1020027009243A patent/KR20020067614A/ko not_active Application Discontinuation
- 2001-01-19 AR ARP010100251A patent/AR030185A1/es unknown
- 2001-01-19 CO CO01003816A patent/CO5261626A1/es not_active Application Discontinuation
- 2001-01-19 PE PE2001000061A patent/PE20011067A1/es not_active Application Discontinuation
-
2002
- 2002-07-09 NO NO20023319A patent/NO323395B1/no not_active IP Right Cessation
- 2002-07-19 US US10/198,073 patent/US6656937B2/en not_active Expired - Fee Related
- 2002-08-20 ZA ZA200206664A patent/ZA200206664B/en unknown
-
2003
- 2003-09-03 US US10/653,188 patent/US20040048859A1/en not_active Abandoned
-
2010
- 2010-02-11 CY CY20101100143T patent/CY1109784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5261626A1 (es) | Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialemente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologica | |
| UY27699A1 (es) | Inhibidores. | |
| CY1109656T1 (el) | Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης | |
| PA8582601A1 (es) | Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia | |
| CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| CR8193A (es) | Piperazina con o sustituida de grupos feniles y su uso como inhibidores de glyt 1 | |
| CY1108744T1 (el) | 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp | |
| GT200100254A (es) | Nuevas imidazotriazinonas sustituidas | |
| CY1106509T1 (el) | Αμιδοακετονιτριλια κατα των παρασιτων του εντερου | |
| CO4900050A1 (es) | Pirrolcarboxanilidas fusionadas; una nueva clase de ligan- dos receptores cerebrales de gaba | |
| CY1108924T1 (el) | Παραγωγα πυρρολιδινης και πιπεριδινης ως ανταγωνιστες νκ1 | |
| DK1200426T3 (da) | Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner | |
| PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
| SV2004001549A (es) | Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| UY28694A1 (es) | Nuevos compuestos | |
| AR035570A1 (es) | Derivados de isotiazol | |
| ES2161945T3 (es) | Nuevos colorantes de oxazina y su utilizacion como marcadores de fluorescencia. | |
| AR055666A1 (es) | Inhibidores inntr | |
| CR8340A (es) | Pirazolilcarboxanilidas n-sustituidas | |
| AR007088A1 (es) | 2,4-diaminopirimidinas sustituidas, compuestos intermedios utilizados en su preparacion, procedimiento para la preparacion de dichas 2,4-diaminopirimidinas sustituidas, medicamentos que las contienen y empleos de dichas pirimidinas | |
| AR069643A1 (es) | Derivados diazenidiolatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| UY28765A1 (es) | Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico | |
| AR050576A1 (es) | Oxadiazolonas con actividad agonista de ppar-delta. composiciones farmaceuticas. | |
| AR028743A1 (es) | DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |